胰臟癌治疗市场规模、份额、成长分析，按治疗类型、按诊断、按给药途径、按最终用户、按分销管道、按地区 - 行业预测，2025-2032 年

2023 年全球胰臟癌治疗市场规模价值 28 亿美元，预计将从 2024 年的 32 亿美元成长到 2032 年的 92.5 亿美元，预测期间（2025-2032 年）的复合年增长率为 14.2%。

据美国癌症协会称，胰腺癌约占美国所有癌症病例的 3%，由于这种棘手疾病的发病率不断上升，预计未来几年胰腺癌治疗市场将大幅增长。胰臟癌通常在晚期才被发现，因此对有效治疗方案的需求日益增加。主要症状包括黄疸和体重减轻，风险因素包括糖尿病和接触某些化学物质。随着企业在感染疾病后重组业务并克服社会隔离和远距工作的最初影响，市场扩张也随之加速。随着我们对肿瘤特征的了解不断加深，个人化的治疗方法在治疗这种恶性癌症方面可能会变得越来越重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

胰臟癌治疗市场规模（依治疗类型划分）

• 市场概况
• 化疗
• 标靶治疗
• 免疫疗法
• 荷尔蒙疗法
• 其他的

胰臟癌治疗市场规模（依诊断）

• 市场概况
• 血液检查
• 切片检查
• 影像检查
• 其他的

胰臟癌治疗市场规模（依给药途径）

• 市场概况
• 口服
• 肠外
• 其他的

胰臟癌治疗市场规模（按最终用户划分）

• 市场概况
• 医院
• 专科门诊
• 居家护理
• 其他的

胰臟癌治疗市场规模（按通路划分）

• 市场概况
• 医院药房
• 零售药局
• 网路药局
• 其他的

胰臟癌治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• AstraZeneca PLC（UK）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Lupin Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Valeant Pharmaceuticals International（Canada）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sinopharm（China）
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd（China）
• EMS SA（Brazil）

结论和建议

Global Pancreatic Cancer Treatment Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.2 billion in 2024 to USD 9.25 billion by 2032, growing at a CAGR of 14.2% during the forecast period (2025-2032).

The pancreatic cancer treatment market is poised for significant growth in the coming years, driven by the rising incidence of this challenging disease, which accounts for approximately 3% of all cancer cases in the U.S., according to the American Cancer Society. With pancreatic cancer often detected at advanced stages, the demand for effective treatment options is on the rise. Key symptoms include jaundice and weight loss, and risk factors range from diabetes to exposure to certain chemicals. The market's expansion is further bolstered by companies restructuring operations post-COVID-19, overcoming earlier disruptions from social isolation and remote work. As understanding of tumor characteristics deepens, personalized treatment approaches will become increasingly critical in managing this aggressive form of cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pancreatic Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pancreatic Cancer Treatment Market Segmental Analysis

Global Pancreatic Cancer Treatment Market is segmented by Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy and Others. Based on Diagnosis, the market is segmented into Blood Test, Biopsy, Imaging Tests and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.Based on diagnosis, the market is segmented into blood test, biopsy, imaging tests, others. By route of administration, the market is segmented into oral, parenteral, and others. By end-user, the market is segmented into hospitals, specialty clinics, homecare, and others. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on region, the pancreatic cancer treatment market segmentation spans North America, Europe, Asia-Pacific, South America, and MEA.

Driver of the Global Pancreatic Cancer Treatment Market

The global market for pancreatic cancer treatment is poised for significant growth primarily due to the rising prevalence of cancer and the corresponding demand for specialized care. With an increasing number of diagnoses linked to genetic factors such as BRCA2 gene mutations, Lynch syndrome, and familial atypical mole-malignant melanoma (FAMMM) syndrome, there is a heightened familial risk for cancer. Additionally, the growing rates of diabetes and obesity contribute to the escalating incidence of pancreatic cancer. Enhanced healthcare spending is also a vital driver, as it improves the existing infrastructure and promotes the development of treatment options. Government initiatives aimed at bolstering healthcare funding further influence market dynamics, paving the way for advancements in pancreatic cancer treatment solutions.

Restraints in the Global Pancreatic Cancer Treatment Market

The global pancreatic cancer treatment market is expected to encounter several restraints that could hinder its growth trajectory. Chief among these is the high cost of treatment, which poses a significant barrier for patients seeking care. Additionally, in many emerging regions, inadequate healthcare infrastructure and a scarcity of skilled medical professionals will further complicate access to effective treatment options. Between 2023 and 2030, stringent regulatory requirements coupled with insufficient public awareness about pancreatic cancer and available therapies are likely to further restrict market expansion, thereby creating challenges for stakeholders aiming to improve patient outcomes in this critical area.

Market Trends of the Global Pancreatic Cancer Treatment Market

The Global Pancreatic Cancer Treatment market is witnessing a significant surge driven by intensifying research and development (R&D) initiatives aimed at innovative therapeutic solutions. With a notable rise in drug discoveries and regulatory approvals, the landscape is becoming increasingly favorable for the introduction of novel treatments. These advancements not only enhance treatment efficacy but also broaden the range of options available to healthcare providers and patients. Furthermore, ongoing collaborations between pharmaceutical companies and research institutions are expected to facilitate the rapid development of targeted therapies, thereby propelling the market's growth trajectory and addressing the critical unmet needs in pancreatic cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pancreatic Cancer Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Global Pancreatic Cancer Treatment Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Biopsy
• Imaging Tests
• Others

Global Pancreatic Cancer Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Pancreatic Cancer Treatment Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pancreatic Cancer Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pancreatic Cancer Treatment Market Size & CAGR (2025-2032)

• North America (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMS S.A. (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations